UNSPSC 51124007: Flecainide monoacetate

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C17H20F6N2O3.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M8U465Q1WQ, chemically known as benzamide, n-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate, but more generally known as flecainide monoacetate, which bears US NIH Compound Identifier 41022.

European Medicines Agency schedules flecainide monoacetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07637MIG. Most nations, for tariff purposes, schedule flecainide monoacetate under HS 29333999. SMILES: CC(=O)O.C1CC(C(CC1OCC(F)(F)F)C(=O)NCC2CCCCN2)OCC(F)(F)F.

UNSPSC 51124007 Flecainide monoacetate is a Commodity code covering a specific antiarrhythmic pharmaceutical active ingredient used in emergency medical response and clinical settings. State and local governments procure this drug as a component of Advanced Life Support medication programs, typically bundled with other injectable cardiac and vasopressor agents for emergency medical services and hospital systems. Issuing bodies soliciting under this code include municipal fire rescue departments, state health agencies, and cooperative purchasing alliances serving multi-jurisdictional public health networks. The procurement pattern shows demand driven by emergency medical services resupply cycles and state Medicaid or pharmacy benefit management programs seeking generic pharmaceutical supply arrangements.

Recent activity reflects two distinct procurement streams: direct municipal emergency services purchasing and statewide cooperative pharmaceutical contracting. The City of Tampa issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications—a four-line-item bundle including epinephrine, labetalol, adenosine, and diltiazem for Tampa Fire Rescue, due April 8, 2026, with estimated contract value of $40,000 and a one-year term plus renewal options; the solicitation included a 5 percent Small Local Business Enterprise bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products across participating states including Oregon, with proposals due March 26, 2026, requiring National Drug Code submissions, cGMP and DSCSA compliance, and distributor relationships with AmerisourceBergen, Cardinal Health, and Morris & Dickson. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking market intelligence on direct-to-manufacturer prescription programs for pharmacy benefit management. Geographic spread spans municipal and state-level procurement in Texas, Minnesota, Oregon, and Florida, with cooperative purchasing expanding the multi-state footprint.